The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.
 
Mark H. O'Hara
Consulting or Advisory Role - Geneos; Natera
Research Funding - Arcus Biosciences; Bristol-Myers Squibb; Celldex; Lilly; Natera; Parker Institute for Cancer Immunotherapy
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Autem Medical (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Gilead Sciences (I); Incyte (I); Ipsen (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Silenseed; Sillajen (I); SOBI; TheraBionic (I); twoXAR; Vector Health (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); MabVax (Inst); Roche (Inst); Silenseed (Inst)
 
Robert A. Wolff
Honoraria - Modern Medicine
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Andrew H. Ko
Honoraria - Clinical Care Options; PER; PlatformQ Health; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Gritstone Bio; Imugene; Ipsen; Roche/Genentech; SynCoreBio
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Halozyme (Inst); Merck (Inst); Merrimack (Inst)
 
Osama E. Rahma
Employment - Outcomes4me
Leadership - Outcomes4me
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting
Consulting or Advisory Role - Alcimed; Bayer; Celgene; Defined Health; Five Prime Therapeutics; Genentech; Gfk; GlaxoSmithKline; Imvax; Leerink; Leerink; Maverick Therapeutics; Merck; PureTech; Putnam Associates; Sobi
Research Funding - Amgen (Inst); Merck
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst)
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Advanced Accelerator Applications; Ipsen
Consulting or Advisory Role - Ipsen; Merck; Taiho Pharmaceutical
Research Funding - Aduro Biotech (Inst); Forty seven (Inst); Genentech/Roche (Inst); Merck (Inst); Newlink Genetics (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
Other Relationship - AstraZeneca; CytomX Therapeutics; Hutchison MediPharma; Silenseed; Taiho Pharmaceutical; Terumo Clinical Supply
 
Jaclyn Paige Lyman
No Relationships to Disclose
 
Christopher R. Cabanski
No Relationships to Disclose
 
Joyson Joseph Karakunnel
Employment - Arcus Biosciences; Innate Pharma; Tizona Therapeutics, Inc.
Leadership - Innate Pharma; PrimeVax; Tizona Therapeutics, Inc.
Stock and Other Ownership Interests - Arcus Biosciences; AstraZeneca; Elucida Oncology; PrimeVax; Tizona Therapeutics, Inc.; Trishula Therapeutics
Patents, Royalties, Other Intellectual Property - Arcus Medimmune
Travel, Accommodations, Expenses - Arcus Biosciences; Innate Pharma; Tizona Therapeutics, Inc.
 
Pier Federico Gherardini
Stock and Other Ownership Interests - TEI Biosciences
Consulting or Advisory Role - TEI Biosciences
 
Lacey J. Kitch
No Relationships to Disclose
 
Samantha Bucktrout
Stock and Other Ownership Interests - Gilead Sciences; Pfizer; Roche
 
Elizabeth Christopher
Employment - Cymabay Therapeutics
Stock and Other Ownership Interests - Cymabay Therapeutics
 
Rosemarie Mick
Stock and Other Ownership Interests - Editas Medicine
 
Richard Chen
Employment - Personalis
Leadership - Personalis
Stock and Other Ownership Interests - Personalis
Patents, Royalties, Other Intellectual Property - Multiple Personalis technology patents
Travel, Accommodations, Expenses - Personalis
 
Ovidiu C. Trifan
Employment - Apexigen
Leadership - Apexigen
Stock and Other Ownership Interests - Apexigen; Bristol-Myers Squibb; Merck
 
Lisa Salvador
Employment - Bristol-Myers Squibb
 
Jill O'Donnell-Tormey
Leadership - HemaCare
Stock and Other Ownership Interests - HemaCare
 
Robert H. Vonderheide
Patents, Royalties, Other Intellectual Property - Inventor on a licensed patient regarding cancer vaccine antigens; Receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody